PHAT Overview

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is25.40 USD with a low forecast of 16.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Phathom Pharmaceuticals Inc revenue for the last quarter amounts to 57.57M USD, increased 94.09

Phathom Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased -100.00

Phathom Pharmaceuticals Inc (PHAT) has 427 emplpoyees as of February 28 2026.

Today PHAT has the market capitalization of 989.71M USD.